#MIGlobal

FDA approvals for five immune checkpoint blockers and three biomarker tests in seven cancers

Nivolung cancernon-squamous 2nd line with biomarker

Pembrolung 2nd line with biomarker

Nivokidney 2nd line

Nivolung cancersquamous 2nd line Nivo

Hodgkin4th line

Atezobladder cancer 2nd line with biomarker

Pembrohead/neck2nd line

Pembro lung cancer1st line with biomarker

Atezolung cancer2nd line

Nivohead/neck2nd line

Nivobladder2nd line

PembroHodgkin4th line

AvelumabMerkel cell Ca1st line

Me

lan

om

aN

on

-Me

lan

om

a 2011 20132012 201620152014 2017 2018

Pembrolizumab2nd-line

Ipilimumabmonotherapy

Nivolumab2nd-line

Nivo1st-line

Ipiadjuvant

Nivo/ipicombo

Pembro1st-line

Nivo melbiomarker

#MIGlobal

Victory Over Cancer

Prevention

Early Much Earlier Detection

Cure Earlier Tumor Burden < 10,000,000 cells

Cure Relapse

Cure Advanced Tumor Burden > 1,000,000,000

Improve Survivorship – Restore Wellness and Healthspan

Celebrate

Solve 10,000 other disease using cancer biology knowledge

Source: World Bank.

#MIGlobal

PCF-VA Precision Oncology Partnership Unprecedented Opportunity for NCI & Industry

Source: World Bank.

Precision Genomic DiagnosisPrecision Prescription Drugs + Cells

#MIGlobal

Exceptional Response – Precision Rx 2016

2.

Targeted PSMA – Alpha Particle Therapy in

Hormone and Chemotherapy Resistant

Metastatic Bone Disease

Kratochwil, C.

University of Heidelberg Precision Immunotherapy Anti PD1 antibody

Exceptional Responses MSH mutant CRPCA

Graff, J.

University of Oregon

1.

PSA= 2104 PSA= 0.01

#MIGlobal

PCF Precision Oncology Program Impact Curability of 16 Other Cancers

Source: Milken Institute.